Institutional investors purchased a net $197.5 thousand shares of OMER during the quarter ended December 2012, and now own 28.75% of the total float, a percentage that is typical for companies in the Biotechnology industry.
| Mutual fund holders | 9.37% |
| Other institutional | 19.39% |
| Individual stakeholders | 10.74% |